呼出气一氧化氮在咳喘患者治疗管理中的研究进展  

Progress of Fractional Exhaled Nitric Oxide in the Management of Patients with Cough and Asthma

作　　者：吴秋惠[1] 张晋萍[1] 葛卫红[1] WU Qiuhui;ZHANG Jinping;GE Weihong(Department of Pharmacy,Nanjing Drum Tower Hospital,Nanjing 210008,China)

机构地区：[1]南京大学医学院附属鼓楼医院药学部,南京210008

出　　处：《医药导报》2022年第6期821-825,共5页Herald of Medicine

基　　金：国家自然科学基金青年基金项目(71704075)。

摘　　要：呼出气一氧化氮(FeNO)被公认为是气道炎症的生物标志物,在呼吸慢病领域得到广泛应用。呼吸与危重症医学科咳喘药学服务门诊是由药学人员协助呼吸科医生开展的管理呼吸慢病患者的新型药学门诊,其服务对象主要为哮喘、慢性咳嗽等慢病患者,该文通过总结FeNO在咳喘患者治疗管理中的研究进展,特别是该技术对预测吸入糖皮质激素治疗反应性、指导治疗方案调整以及疾病控制水平评估的相关研究,以期为药学人员参与呼吸道炎症疾病管理提供新的思路与策略。Fractional exhaled nitric oxide(FeNO)is recognized as a biomarker of airway inflammation and is widely used in the field of chronic respiratory diseases.Pulmonary and critical care medicine(PCCM)pharmaceutical service clinic is a new type of respiratory service clinic to manage patients with chronic respiratory diseases.This paper summarizes the research progress of FeNO in the treatment and management of patients with chronic respiratory diseases,especially the prediction of inhaled corticosteroids(ICS)treatment response,the adjustment of treatment plan and the evaluation of disease control level,in order to provide new ideas and strategies for pharmaceutical personnel to participate in the management of respiratory airway inflammatory diseases.

关 键 词：呼出气一氧化氮 咳喘 治疗管理 

分 类 号：R974.3[医药卫生—药品] R562.25[医药卫生—药学]